Patents Examined by Yong D. Pak
  • Patent number: 12385074
    Abstract: A method is described for producing an L-amino acid including the steps of cultivating in a culture medium an L-amino acid-producing bacterium belonging to the family Enterobacteriaceae to produce and accumulate the L-amino acid in the culture medium, cells of the bacterium, or both, and collecting the L-amino acid from the culture medium, the cells, or both, wherein said bacterium has been modified to overexpress a gene encoding a periplasmic adaptor protein.
    Type: Grant
    Filed: September 27, 2021
    Date of Patent: August 12, 2025
    Assignee: AJINOMOTO CO., INC.
    Inventors: Natalia Viktorovna Stoynova, Olga Nikolaevna Igonina, Evgeniya Aleksandrovna Malykh, Natalya Sergeevna Plekhanova, Irena Alexandrovna Kononova, Ivan Alexandrovich Butov, Viktor Vasilievich Samsonov, Irina Vladimirovna Biryukova, Irina Segreevna Shmagina
  • Patent number: 12385050
    Abstract: A biopesticide composition and a method of making the composition. The biopesticide composition comprises a biopesticide in the form of an endotoxin protein, preferably a ?-endotoxin; and a late embryogenesis abundant (LEA) protein in the form of a LEA2/dehydrin protein, wherein the ratio of endotoxin to LEA2/dehydrin proteins is 1:40. The LEA2/dehydrin proteins in the composition confers heat resistance to the endotoxin up to a temperature of about 42° C. The method of making the biopesticide composition comprises providing a biopesticide, providing a LEA protein, by isolating genes for a LEA protein from a plant and expressing the isolated gene for the LEA protein in an expression vector to produce a recombinant LEA protein, the method including combining the biopesticide and the LEA protein.
    Type: Grant
    Filed: May 7, 2024
    Date of Patent: August 12, 2025
    Assignee: United Arab Emirates University
    Inventors: Khaled Masmoudi, Mughair Abdul Aziz
  • Patent number: 12359176
    Abstract: Integral membrane proteins capable of transporting melatonin and other indole-derivatives across biological membranes, and uses thereof.
    Type: Grant
    Filed: March 13, 2020
    Date of Patent: July 15, 2025
    Assignee: Danmarks Tekniske Universitet
    Inventors: Douglas Bruce Kell, Lei Yang, Sailesh Malla
  • Patent number: 12359184
    Abstract: The present invention relates to the use of glutamine synthetase as a protein therapy (such as enzyme replacement protein therapy) for the treatment of hyperammonemia. In particular the invention relates to the systemic administration of glutamine synthetase. The glutamine synthetase may be provided in conjugated or fusion form, to increase its half-life in the circulation. Also provided is a pharmaceutical composition comprising glutamine synthetase. The invention also relates to the uses, methods and compositions involving a combination of the glutamine synthetase protein and an ammonia lowering agent, such as a nitrogen scavenger.
    Type: Grant
    Filed: May 24, 2018
    Date of Patent: July 15, 2025
    Assignee: Thoeris GmbH
    Inventor: Tamara Nicolson
  • Patent number: 12351841
    Abstract: The present invention relates to variants of an alpha-amylase which have an increased exoamylase activity compared to the parent alpha-amylase. The present invention also relates to methods of making the variant alpha-amylase and the use of the variant alpha-amylase in baking, detergents, personal care products, in the processing of textiles, in pulp and paper processing, in the production of ethanol, lignocellulosic ethanol or syrups and as viscosity breaker in oilfield and mining industries.
    Type: Grant
    Filed: May 29, 2019
    Date of Patent: July 8, 2025
    Assignee: BASF SE
    Inventors: Hugo Urbina, Asfia Qureshi, Adrienne Huston Davenport, Xuqiu Tan, Jochen Kutscher, Andreas Funke, Michael Seitter, Stefan Haefner, Anh-Huy Phan Le
  • Patent number: 12344871
    Abstract: It is an object of the present invention to provide a practical means of producing cysteine from glutathione that is also suitable for use in the field of foods. Cysteine is produced from glutathione by a first step of producing cysteinylglycine by the action of a ?-glutamyl peptidase derived from a microorganism on reduced glutathione; and a second step of producing cysteine by the action of an acid protease derived from a microorganism on the cysteinylglycine.
    Type: Grant
    Filed: June 17, 2020
    Date of Patent: July 1, 2025
    Assignees: AMANO ENZYME INC., AMANO ENZYME EUROPE LTD.
    Inventor: Hiroki Fujioka
  • Patent number: 12338471
    Abstract: The present invention relates to the use of glutamine synthetase as a protein therapy (such as enzyme replacement protein therapy) for the treatment of hyperammonemia. In particular the invention relates to the systemic administration of glutamine synthetase. The glutamine synthetase may be provided in conjugated or fusion form, to increase its half-life in the circulation. Also provided is a pharmaceutical composition comprising glutamine synthetase. The invention also relates to the uses, methods, and compositions involving a combination of the glutamine synthetase protein and an ammonia lowering agent, such as a nitrogen scavenger.
    Type: Grant
    Filed: June 3, 2022
    Date of Patent: June 24, 2025
    Assignee: Thoeris GmbH
    Inventor: Tamara Nicolson
  • Patent number: 12331336
    Abstract: A recombinant strain of F. diplosiphon was made by transforming wild type F. diplosiphon with a pGEM-7Zf (+) plasmid containing the photolyase gene (phrA) via electroporation. The recombinant strain was designated B481-ViAnSa and overexpressed the phrA gene to result in enhanced UV tolerance compared to wild type F. diplosiphon.
    Type: Grant
    Filed: August 19, 2022
    Date of Patent: June 17, 2025
    Assignee: Morgan State University
    Inventors: Viji Sitther, Samson Gichuki
  • Patent number: 12331325
    Abstract: The present disclosure provides engineered transaminase polypeptides useful for the synthesis of chiral amine compounds under industrially relevant conditions. The disclosure also provides polynucleotides encoding the engineered transaminase polypeptides, host cells capable of expressing the engineered transaminases, and methods of using the engineered transaminases for the production of chiral amine compounds.
    Type: Grant
    Filed: September 1, 2023
    Date of Patent: June 17, 2025
    Assignee: Codexis, Inc.
    Inventors: Scott J. Novick, Nikki Dellas
  • Patent number: 12325872
    Abstract: This invention provides acid decarboxylase-prion subunit fusion polypeptides, nucleic acid sequences, expression vectors, and host cells expression such fusion polypeptides to produce various amino acids and derivatives of the amino acids such as polyamines.
    Type: Grant
    Filed: April 13, 2023
    Date of Patent: June 10, 2025
    Assignees: CATHAY BIOTECH INC., CIBT America Inc.
    Inventors: Howard Chou, Ling Chen, Wenqiang Lu, Xiucai Liu
  • Patent number: 12319943
    Abstract: Provided is a mutant protease with improved stability under acidic condition. A mutant protease that consists of the amino acid sequence as shown in SEQ ID NO:2 or an amino acid sequence having an identity of at least 90% thereto, in which the amino acid residue at a position corresponding to position 303 in the amino acid sequence as shown in SEQ ID NO:2 is substituted with another amino acid residue.
    Type: Grant
    Filed: March 6, 2020
    Date of Patent: June 3, 2025
    Assignee: Kao Corporation
    Inventor: Masatoshi Tohata
  • Patent number: 12312611
    Abstract: The invention relates to engineered terminal deoxynucleotidyl transferase (TdT) enzymes or the homologous amino acid sequence of Pol?, Pol?, Pol?, and Pol? of any species or the homologous amino acid sequence of X family polymerases of any species and their use in a method of nucleic acid synthesis, to methods of synthesizing nucleic acids, and to the use of kits comprising said enzymes in a method of nucleic acid synthesis. The invention also relates to the use of new terminal deoxynucleotidyl transferases and 3?-blocked nucleoside triphosphates in a method of template independent nucleic acid synthesis.
    Type: Grant
    Filed: February 4, 2020
    Date of Patent: May 27, 2025
    Assignee: Nuclera, Ltd.
    Inventors: Michael Chun Hao Chen, Gordon Ross McInroy, Sihong Chen, Ian Haston Cook
  • Patent number: 12312620
    Abstract: Herein is disclosed a process for effectively precipitating phytase as a complex with a polyanion, as well as compositions comprising phytase and a polyanion, and a method for manufacturing such compositions.
    Type: Grant
    Filed: November 29, 2022
    Date of Patent: May 27, 2025
    Assignee: AB Enzymes Oy
    Inventors: Katja Palmunen, Mirkka Perkkalainen, Leena Lehtikari, Imke Kühn
  • Patent number: 12281337
    Abstract: The invention relates to a GDSL lipase, genetically-engineered bacteria and an application thereof. The GDSL lipase is derived from Streptomyces diastaticus CS1801 and its amino acid sequence is as shown in SEQ ID NO.2. After construction of a genetically-engineered bacterium strain, a GDSL lipase is generated through fermentation. Through this enzyme, vitamin A and palmitic acid are converted to produce vitamin A palmitate. The content of the vitamin A palmitate obtained from the conversion is 16.35 mg/L at most. The conversion efficiency is 81.75% at most. This lipase provides a new path to synthesize vitamin A palmitate by the enzymatic method and has an important application prospect.
    Type: Grant
    Filed: June 27, 2023
    Date of Patent: April 22, 2025
    Assignees: Suzhou Kemanduo Biotechnology Co., Ltd., Changshu Institute of Technology
    Inventors: Bin Qi, Manting Qi, Limei Wang, Yuhua Wang
  • Patent number: 12258598
    Abstract: A ?-glycosidase SS-BGL mutant for modifying ginsenoside and application thereof are provided, which relate to the field of genetic engineering technologies. The ?-glycosidase SS-BGL mutant is ?-glycosidase SS-BGL with the amino acid sequence as shown in SEQ ID NO: 1 having mutation at one or more sites. A single-site mutation includes: A1, making glutamine at 96th position of SEQ ID NO: 1 to be mutated to glutamic acid; A2, making asparagine at 97th position of SEQ ID NO: 1 to be mutated to aspartate; A3, making asparagine at 128th position of SEQ ID NO: 1 to be mutated to aspartate; A4, making asparagine at 302th position of SEQ ID NO: 1 to be mutated to aspartate. A double-site mutation is a combination of A3 and A4, a three-site mutation is a combination of A1, A2 and A4, and a four-site mutation is a combination of A1, A2, A3 and A4.
    Type: Grant
    Filed: April 18, 2024
    Date of Patent: March 25, 2025
    Assignee: Northwest university
    Inventors: Weina Li, Daidi Fan
  • Patent number: 12258593
    Abstract: The present invention provides a novel hydrolase that can industrially produce optically highly pure (1S,2S)-1-alkoxycarbonyl-2-vinylcyclopropane carboxylic acid with high efficiency at low costs, and a production method using the hydrolase.
    Type: Grant
    Filed: December 30, 2022
    Date of Patent: March 25, 2025
    Assignee: UBE CORPORATION
    Inventors: Toyokazu Yoshida, Koichi Ishida, Ryoma Miyake, Takanobu Iura, Hiroshi Kawabata
  • Patent number: 12241094
    Abstract: Provided herein are phenazine degrading agents, methods and systems for interfering with viability of bacteria and related antimicrobial and compositions.
    Type: Grant
    Filed: September 21, 2020
    Date of Patent: March 4, 2025
    Assignee: CALIFORNIA INSTITUTE OF TECHNOLOGY
    Inventors: Dianne K. Newman, Kyle C. Costa
  • Patent number: 12234465
    Abstract: Genetically modified microorganisms that have the ability to convert carbon substrates into chemical products such as isobutanol are disclosed. For example, genetically modified methanotrophs that are capable of generating isobutanol at high titers from a methane source are disclosed. Methods of making these genetically modified microorganisms and methods of using them are also disclosed.
    Type: Grant
    Filed: July 11, 2022
    Date of Patent: February 25, 2025
    Assignee: PRECIGEN, INC.
    Inventors: Jeffrey David Orth, Louis A. Clark, Lily Yuin Chao, Na My Trinh, Christopher Cheyney Farwell, Xinhua Zhao, Matthias Helmut Schmalisch, Grayson Thomas Wawrzyn, Xuezhi Li, Mark Anton Held, Kevin Lee Dietzel, James Kealey
  • Patent number: 12227771
    Abstract: Expression systems for the expression of an ?9?10 nicotinic acetylcholine receptor (nAChR) are described. Also described are methods of using the expression systems to identify agonists, antagonists, or allosteric modulators of an ?9?10 nAChR.
    Type: Grant
    Filed: May 15, 2020
    Date of Patent: February 18, 2025
    Assignee: JANSSEN PHARMACEUTICA NV
    Inventors: David S. Bredt, Weston Davini, Shenyan Gu, Jose Matta, Min Lei O'Carroll
  • Patent number: 12221637
    Abstract: The present invention relates to polypeptides having nuclease activity, and polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and recombinant host cells comprising the polynucleotides as well as methods of producing, recovering and using the polypeptides. The invention further relates to cleaning compositions comprising one or more of the polypeptides having nuclease activity, as well as a cleaning method and use of the polypeptides.
    Type: Grant
    Filed: October 3, 2019
    Date of Patent: February 11, 2025
    Assignee: Novozymes A/S
    Inventors: Tianqi Sun, Jesper Salomon, Klaus Gori, Morten Gjermansen, Marc Dominique Morant, Mary Ann Stringer